UBS Group
TERN

UBS Group’s Terns Pharmaceuticals TERN Stock Holding History

UBS Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.8M Buy
1,228,726
+902,758
+277% +$37.1M 0.01% 1384
2025
Q4 		$13.2M Sell
325,968
-646,804
-66% -$14.9M ﹤0.01% 3009
2025
Q3 		$7.31M Sell
972,772
-198,847
-17% -$1.27M ﹤0.01% 3633
2025
Q2 		$4.37M Buy
1,171,619
+238,513
+26% +$745K ﹤0.01% 4023
2025
Q1 		$2.58M Buy
933,106
+531,448
+132% +$2.17M ﹤0.01% 4478
2024
Q4 		$2.23M Buy
401,658
+332,260
+479% +$2.25M ﹤0.01% 4626
2024
Q3 		$579K Sell
69,398
-17,934
-21% -$148K ﹤0.01% 5113
2024
Q2 		$595K Buy
87,332
+24,563
+39% +$149K ﹤0.01% 4872
2024
Q1 		$412K Sell
62,769
-45,706
-42% -$298K ﹤0.01% 5351
2023
Q4 		$704K Buy
108,475
+86,931
+404% +$460K ﹤0.01% 4801
2023
Q3 		$108K Sell
21,544
-31,531
-59% -$200K ﹤0.01% 5779
2023
Q2 		$464K Buy
53,075
+47,403
+836% +$552K ﹤0.01% 4884
2023
Q1 		$67.2K Buy
+5,672
New +$54.2K ﹤0.01% 6218
2022
Q4 		– Sell
-3,667
Closed -$22K – 11144
2022
Q3 		$22K Buy
+3,667
New +$13.6K ﹤0.01% 7270
2022
Q1 		– Sell
-3,775
Closed -$27K – 10890
2021
Q4 		$27K Buy
+3,775
New +$31.4K ﹤0.01% 7506
2021
Q2 		– Sell
-2,546
Closed -$56K – 9819
2021
Q1 		$56K Buy
+2,546
New +$55.8K ﹤0.01% 6433

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

UBS Group's TERN Position: Q1 2026 in Review

UBS Group increased its Terns Pharmaceuticals (TERN) stake by 277% in Q1 2026, buying an estimated $37.1M and bringing the position to 1,228,726 shares worth $64.8M. The position accounts for 0.01% of the portfolio, ranked #1384.

UBS Group first reported a position in TERN in Q1 2021 and has held it in 16 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • UBS Group held 1,228,726 shares of Terns Pharmaceuticals worth $64.8M as of Q1 2026.
  • UBS Group bought 902,758 Terns Pharmaceuticals shares in Q1 2026, an estimated $37.1M.
  • Terns Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q1 2026, its #1384 holding.
  • UBS Group first reported a position in Terns Pharmaceuticals in Q1 2021 and has held it in 16 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.